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Takotsubo cardiomyopathy (TTC) is an acute and reversible cardiac wall motion
abnormality of the left myocardium. Although many studies focused on etiology,
diagnostic and treatment of TTC, precise clinical guidelines on TTC are not available.
Research revealed emotional and physical triggering factors of TTC and emphasized
the association of TTC with psychiatric and particularly acute neurological disorders.
Similar clinical presentation of acute coronary syndrome (ACS) and TTC patients, makes
an anamnestic screening for TTC risk factors necessary. In psychiatric anamnesis
affective disorders and chronic anxiety disorders are presumably for TTC. Subarachnoid
hemorrhages and status epilepticus are typical acute neurological associated with
a higher risk for TTC. Moreover, magnetic resonance imaging (MRI) studies reveled
brain alterations of the limbic system and reduced connectivity of central autonomic
nervous system structures. Diagnosis of TTC is made by elevation of cardiac enzymes,
electrocardiogram (ECG) and visualization of myocardial wall motion. Major differential
diagnoses like acute coronary syndrome and myocarditis are hereby in synopsis with
anamnesis with respect of possible emotional and physical triggering factors of TTC ruled
out. In most cases the TTC typical wall motion abnormalities resolve in weeks and therapy
is only necessary in hemodynamic instable patients and if rare complications, like cardiac
wall ruptures occur. Recently, the two-parted International expert consensus document
on Takotsubo syndrome was published, providing a detailed characterization of TTC and
allows clinicians to understand this cardiac dysfunction with a multidisciplinary view.
Keywords: Takotsubo (stress) cardiomyopathy, autonomic (vegetative) nervous system, psychiatric disorders,
neurological disorders, affective disorders
INTRODUCTION
Takotsubo cardiomyopathy (TTC), also known as left ventricular apical ballooning syndrome
(LVBS), transient apical ballooning, stress cardiomyopathy, or broken heart syndrome, is an acute
and reversible wall motion abnormality classically of the left ventricularmyocardium andwas firstly
described by Sato et al. (1) and Ghadri et al. (2). The Japanese term “Takotsubo” means “octopus
pot” and describes the characteristic left ventricular end-systolic apical ballooning phenomenon,
which can be visualized in transthoracic echocardiogram (TTE) or coronary angiography with
left ventriculography. The classical morphological pattern of TTC is an apical akinesia with basal
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hyperkinesia of the left ventricular myocardium (3). However,
there have been further wall motion abnormalities in TTC
described, such as basal, midventricular, and lateral akinesia of
the left ventricular myocardium and also involvement of the right
ventricular myocardium as part of a biventricular involvement or
isolated right ventricular wall motion abnormality (3). Typically,
TTC patients present with clinical symptoms suggestive for an
acute coronary syndrome (ACS), such as chest pain, dyspnea,
syncope, and nausea with sudden onset after an emotional
or physical stressor (4). From an epidemiological point of
view patients diagnosed with TTC are typically postmenopausal
female patients with a mean age of 66.8 years (5, 6). However, the
epidemiology of TTC was shown to be more complex according
to various retrospective studies. Biomarkers used in diagnosis of
TTC are the cardiac enzymes troponin, creatine kinase, and N-
terminal prohormone of brain natriuretic peptide (NT-proBNP),
which are classically elevated, but show lower peak values than
in patients with ACS. Although, ECG changes in TTC patients
are not specific, most commonly ST-elevations in leads II, III,
aVF, aVR, and V5 to V6 are seen (7). Additionally, repolarization
abnormalities (T-wave inversions) are commonly seen in ECGs
of TTC patients, as well as QTc-prolongations. Recently,
the International Takotsubo Diagnostic Criteria (InterTAK
Diagnostic Criteria) as part of an international expert consensus
document have been published and support differentiation of
TTC patients with no ST-elevation in ECG and ACS patients (8).
The clinical challenge in emergency rooms is to rule out an ACS
as most important differential diagnosis of TTC. Moreover, acute
infectious myocarditis or pericarditis are relevant differential
diagnoses of TTC. Complications of TTC include ventricular
arrhythmias, acute heart failure with cardiogenic shock as a
result of primary pump failure or left ventricular outlet tract
obstruction, whereas rare complications are cardiac wall ruptures
or formation of left ventricular thrombus (2, 9). Generally, the
wall-motion abnormalities normalize within hours to weeks in
TTC patients (9). We reviewed the current available literature
to outline the pathophysiological mechanisms of TTC, focusing
on linking TTC to psychiatric, and neurological disorders.
Moreover, we briefly describe the diagnostical workflow in
emergency rooms of patients with suggested TTC. We conclude




The incidence and prevalence of TTC are reported to be
increasing, certainly due to a more sensitive clinical screening of
patients in e.g., chest pain units for TTC. Deshmukh et al. studied
the occurrence of TTC from the Nationwide Inpatient Sample
database of US hospitalizations based on the International
Classification of Diseases (ICD) in 2008 and demonstrated that
0.02% of all patients hospitalized in the US were diagnosed
with TTC (10). Two percent of patients with clinical suspected
ACS were diagnosed with TTC (7). Interestingly, data derived
from the International Takotsubo Registry revealed patients
characteristics with TTC in the United States and Europe and
showed that of 1,750 studied patients diagnosed with TTC
89.8% were postmenopausal women with a mean age of 66.8
years (5, 6). Importantly, higher in-hospital mortality rates of
male TTC patients compared to female TTC patients have
been observed retrospectively (11, 12). However, Patel et al.
found in their analysis no significant sex difference in respect
of overall mortality rates of TTC patients aged ≥50 years (11).
Remarkably, a significant higher prevalence of neurologic or
psychiatric disorder rates among TTC patients compared to ACS
patients has been reported (5). Additionally, male TTC patients
≥50 years showed physical triggers prior to the onset of TTC
more often, whereas female TTC patients ≥50 years seem to
suffer from premorbid psychiatric disorders more frequently
(11). Notably, female patients showed higher recurrence rates of
TTC compared to male TTC patients (11). Singh et al. detected
an annual rate of TTC recurrence of 1.5% (13). Moreover,
one retrospective analysis revealed a TTC recurrence of 6.1%
during a follow up period of 6 years (14). Effectiveness of
pharmacologic therapy in order to prevent reoccurrence of TTC
is under current investigation. Tendentially, prescription of ACE-
inhibitors is reported to be inversely correlated to recurrence of
TTC in retrospective analysis (15). Furthermore, β2-adrenergic




The underlying pathophysiological mechanism of TTC is
not completely understood until today. Over the last decades
numerous animal experiments and clinical studies have been
conducted to elucidate the pathophysiology of TTC, outlining
TTC as a multifactorial acute, and reversible cardiac disorder.
Nevertheless, it is unquestioned that emotional and physical
stress are frequent triggers of TTC (17). Initially, Sato et al.
explained the pathophysiology of TTC with simultaneous
spasms of coronary arteries (1, 18). The theory of simultaneous
coronary vasospasm as underlying mechanism of TTC was
disproved, as endomyocardial biopsies taken from TTC
patients showed histopathological patterns of myocardial
abnormalities, which are not characteristic for infarcted,
stunned or hibernating myocardium (7). Furthermore, coronary
microvascular dysfunction as etiology of TTC has been studied,
but data are still not distinct up to now (7, 9).
However, an association of increased sympathetic activity
resulting in systemic blood catecholamine excess, and TTC
has been demonstrated in numerous studies (2). Some
authors discuss increased blood catecholamine levels rather
as a triggering factor than an underlying pathophysiological
mechanism of TTC. Interestingly, to date only one study showed
extremely high plasma concentrations of catecholamines,
whereas other studies showed nearly normal catecholamine
blood levels in TTC patients (9). Research has drawn attention
to the role of β2-adrenoceptors, as high epinephrine blood levels
induce a β2-adrenoceptor coupling change from membranous
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FIGURE 1 | Linking neurological and psychiatric disorders to Takotsubo cardiomyopathy.
Gs proteins to Gi proteins with a consecutive negative inotropic
effect (19). Therefore, the reversible nature of ventricular
ballooning after normalization of catecholamine blood levels
could be explained by these compensatory biochemical
processes. Additionally, regional differences in myocardial
expression of β2-adrenergic receptor density have been
shown, which mediate the cellular effects of the increased
catecholamine blood concentrations and explain the regional left
ventricular myocardial stunning (2). Besides circulating blood
catecholamines, secreted from the adrenal medulla, ventricular
sympathetic nerve fiber terminals release norepinephrine
and a hyperactivation of these cardiac sympathetic nerve
terminals with increased synaptic norepinephrine levels and
consecutive activation of post-synaptic α1-, β1-, and β2–
receptors as leading pathomechanism is discussed currently.
However, sympathetic nerve fiber density is higher in basal
myocardium as in ventricular myocardium and therefore
blood circulating epinephrine seems to have a greater influence
on apical ventricular myocardium then norepinephrine
released from the sympathetic nerve terminals in apical
myocardium (19) (Figure 1).
Recent research on the pathogenesis of TTC demonstrated
an association of inflammatory myocardial processes in
TTC patients, linking catecholamine stress-induced TTC to
inflammatory responses of the myocardium in experimental
animal studies. Wilson et al. characterized the myocardial
inflammatory response in TTC based on animal experimental
studies with catecholamine induced TTC, showing a
predominant myocardial M1 macrophages infiltration in
TTC without a switch of M1 macrophages (proinflammatory
tissue destructive) to M2 macrophages (anti-inflammatory
tissue reparative/profibrotic) (20). Importantly, Wilson et al.
found in their study a positive correlation of increasing EF
with the percentage of M2 macrophages (20). However, it
remains to be elucidated, whether inflammatory myocardial
processes are occurring prior TTC or are results of TTC in
further animal-based experimental and clinical studies, in
order to develop specific therapeutic strategies. Not only local
myocardial inflammatory processes have been described, but
also persistent systemic peripheral inflammatory response
in TTC patients has been studied, making potential long
term pharmacological anti-inflammatory treatment of TTC
considerable. Systemic peripheral inflammation denoted in
elevated serum levels of interleukin-6, chemokine ligand 1,
CD14++CD16− monocytes, and non-classical CD14+CD16++
monocytes have been described in clinical studies (21). Whereas,
serum levels of intermediate CD14++CD16+ monocytes and
non-classical CD14+CD16++ monocytes were reduced (21).
Scally et al. reported persistent peripheral systemic inflammation
processes in TTC patients in follow-up measurements of
pro-inflammatory cytokines, whereby serum concretions of
interleukin 6 and interleukin 8 remained elevated (21). In
clinical settings inflammatory processes in context of TTC can be
visualized as myocardial edema in cardiac magnetic resonance
imaging (MRI) more favorable in T2 weighted imaging of the
myocardium (21, 22).
Recent studies focus on cardiac ion channel activity
modulated by inflammatory cytokines and the resulting
change of cardiac action potential duration, which should be
mentioned as an association of inflammation and TTC has been
previously described. It has been postulated, that both circulating
cytokines directly affect ion channels of cardiomyocytes and
indirectly increase the risk for the occurrence of cardiac
electrophysiological disturbance through increased sympathetic
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output from central and peripheral autonomic nervous system
nerve fibers (23). These changes in cardiac action potentials
are mainly pictured through QTc prolongation in ECG and has
been proven to be associated with high blood levels of acute
phase proteins (23). An increase of QT interval is therefore
called an acquired cardiac channelopathy. The suggested
pathophysiological mechanisms are both changes in expression
and function of potassium and calcium channels (23). It has
been demonstrated, that IL-1β and IL-6 enhance cardiac calcium
channels (23). Contrary, potassium channels have been reported
to be reduced expressed via activation of TNFα pathways
(23). Interestingly, so far no studies demonstrated a change of
expression or function of cardiac sodium channels via cytokines
(23). Moreover, an inflammatory reflex has been described
in patients with QT prolongation. The underlying cardiac
changes are mediated through a cytokine mediated central
activation of sympathetic nerve fibers. As a consequence of this
activation cytokine production and activation of β2-adrenergic
receptors expressed in circulating lymphocytes and monocytes
is decreased (23). The sympathetic nerve fiber activation
results in cardiac activation of calcium and potassium channels
leading to increased duration of cardiac action potential (23).
Increased calcium ion influx and decreased potassium eﬄux
from cardiomyocytes results in an increase of cardiac action
potential and therefore a prolongation of the QT interval (24).
Additionally, studies have shown an strong association of high
c-reactive protein blood levels and QT interval prolongation
(24). Not only acute phase proteins have been demonstrated
to modulate cardiac ion channel function, but also antibodies,
e.g., anti-Sjögren’s-syndrome-related antigen A have been found
to influence potassium channels of ventricular cardiomyocytes
resulting in QT prolongation (25).
Numerous studies suggested the existence of genetic
predisposition for TTC. Genetic polymorphisms for cardiac α1-,
β1-, and β2-adrenergic receptors, GRK5, and estrogen receptors
have been described (3). However, the genetic associates need to
be evaluated in larger TTC cohorts in the future.
TAKOTSUBO CARDIOMYOPATHY AND
NEUROLOGICAL DISORDERS
Multiple clinical cases of emerging TTC after acute disorders
of the central nervous system published. Over the last decades
remarkable interactions of the brain and heart derived from
clinical complications of patients with neurological disorders
followed or accompanied by newly cardiac disorders have
been described. Hence, the term brain-heart-syndrome was
introduced compromising cardiac damage following brain
disorders (26). Table 1 summarizes the key studies of the
association of TTC and neurological and psychiatric disorders.
Common acute neurological disorders associated with
the occurrence of TTC are ischemic strokes, subarachnoid
hemorrhages and seizures (2). Whereas, subarachnoid
hemorrhages were found to be strongly associated with
TTC in various studies. In a recently published cross-sectional
study the strongest associations between acute neurological
diseases with following TTC have been found for subarachnoid
hemorrhages, status epilepticus and less commonly for
seizures (27). Interestingly, Morris et al reported a negative
association of traumatic brain injury and TTC (27). Further
neurological disorders associated with TTC are transient global
amnesia, meningoencephalitis, migraine headache, intracerebral
hemorrhage and ischemic stroke (27). In one study patients
with aneurysmal subarachnoid hemorrhage induced TTC
showed a high association with inter alia (i.a.) following cerebral
vasospasm, pulmonary edema and longer duration of intubation
(28). Hence, acute neurological disorders are counted to be
an important physical trigger of TTC and every patient with
symptoms suggestive for ACS should be worked up carefully
regarding possible TTC. Over the last decades research focused
on the hypothalamic-pituitary-adrenal axis (HPA-axis) as major
neuroendocrine system regulating the release of i.a. cortisol
from the adrenal gland, shifting the metabolism to higher stress
levels (26). Higher serum cortisol levels have been correlated
with stroke severity and insular damage (26). Additionally,
the sympathetic activity levels are increased in patients with
ischemic stroke due to activation of the HPA axis, resulting
in i.a. significant increases of catecholamine blood levels.
Those lead to higher risks of occurrence of arrhythmias and
myocardial damage with resulting inflammatory responses of
the affected myocardial area (26, 29). Local myocardial necrosis
can lead to advanced inflammatory processes with antigen-
dependent autoimmunity and exaggerated immune-mediated
tissue damage, which needs to be further investigated in TTC
patients (29). Furthermore, animal studies have shown an
increase of plasma catecholamine levels after ischemic stroke,
which is directly proportional to the incidence of myocardial
damage followed by cardiac damage (26). Especially, ischaemic
or hemorrhage stroke of the insular cortex are reported to have
major influence on cardiac function (26). Interestingly, the right
hemisphere seems to control the sympathetic activity, whereas
the left hemisphere regulates parasympathetic activity (26).
For example infarctions of the left hemisphere of the brain are
associated with arrhythmias, a decreased cardiac wall motion
and an increased risk of adverse cardiac outcome (26).
Moreover, anatomical brain alterations have been described
in TTC patients. A MRI study performed with a TTC cohort
derived from the International Takotsubo Registry visualized
reduced gray-matter volume of structures in the brain areas
of the limbic system, such as the amygdala, insula, cingulate
cortex and hippocampus in patients with TTC (30). However, it
remains to be elucidated, whether these anatomic abnormalities
are pathophysiological factors contributing to the pathogenesis
of TTC or the consequence of TTC (30). Furthermore, cerebral
MRI imaging of TTC patients has shown a reduced connectivity




In general, prevalence rates of psychiatric and neurological
disorders are reported to be high in patients with TTC (2,
5). Also, TTC patients have been found to have higher rates
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TABLE 1 | Key studies on association between Takotsubo cardiomyopathy with neurological and psychiatric disorders.
Study Study type Number of patients Associated neurological psychiatric disorder
Morris et al. (27) Cross-sectional retrospective
analysis
National inpatient sample TTC with acute
neurological disorder = 155,105 TTC
without acute neurological disorder =
149,273
Association of TTC with following acute neurological
disorders: SAH (OR 11.7; 95% CI 10.2–13.4), status
epilepticus (OR 4.9; 95% CI 3.7–6.3), seizures (OR 1.3;
95% CI 1.1–1.5), transient global amnesia (OR 2.3; 95%
CI 1.5–3.6), meningoencephalitis (OR 2.1; 95% CI
1.7–2.5), migraine (OR 1.7; 95% CI 1.5–1.8),
intracerebral hemorrhage (OR 1.3; 95% CI 1.1–1.5), and
ischemic stroke (OR 1.2; 95% CI 1.1–1.3. Traumatic
brain injury is negative associated with TTC (OR 0.7;
95% CI 0.6–0.9)
Lee et al. (28) Cross-sectional retrospective
analysis
Mayo Clinic neurological intensive care unit
SAH-induced TTC = 8 No controls
Association of TTC with aneurysmal SAH with following
cerebral vasospasm (n = 6) and pulmonary edema
(n = 5)
Templin et al. (5) Cross-sectional retrospective
analysis
International Takotsubo registry TTC =
455 ACS = 455
55.8% of TTC patients had history or an acute episode
of neurologic or psychiatric disorder, whereas only
25.7% ACS patients had neurological psychiatric
disorder (P < 0.001)
ACS, acute coronary syndrome; SAH, subarachnoid hemorrhage; TTC, Takotsubo cardiomyopathy.
of psychiatric and neurological disorders compared to ACS
patients (2). Common predisposing triggering factors of TTC
are life events associated with emotional (e.g., panic or anxiety,
surprise birthday parties) and physical (e.g., acute respiratory
failure or central nervous system conditions) stress (5, 31).
More recent data have shown, that emotional triggers are
not as common as physical triggers in TTC patients (5).
More specific, existing physical triggers of TTC were found
to be independent predictors for in-hospital complications (5).
Noteworthy, female TTC patients reported more anamnestic
emotional triggers prior the occurrence of TTC than male TTC
patients, who showed physical triggers prior to the onset of
TTC more often (5). Smeijers et al. demonstrated in a small
retrospective analysis TTC patients exhibit significant higher
levels of depressive symptoms in well-established Patient Health
Questionnaire compared to healthy controls (32). Additionally,
data derived from the International Takotsubo Registry revealed
that 42.3% of studied TTC patients were diagnosed with a
psychiatric disorder, whereby 50.0% of these TTC patients had
an affective disorder (5). El-Sayed et al. demonstrated within
a large retrospective demographic analysis comparing TTC
patients with orthopedic and myocardial infarction patients that
TTC patients had higher risk for substance abuse (drug and
alcohol abuse) (33). Additionally, the intake of medication to
treat affective disorders such as selective norepinephrine reuptake
inhibitors, serotonin reuptake inhibitors, or benzodiazepines
was reported to be more prevalent in TTC patients than in
healthy controls (2, 5). Moreover, TTC patients are reported
to not have significantly higher general anxiety levels than
healthy controls, but higher levels of illness-related anxiety levels
(32). Another study showed a high prevalence of diagnosed
chronic anxiety disorder prior to the occurrence of TTC (34).
Additionally, preadmission anxiety has been found in a case
control study to be associated with the occurrence of TTC (35).
Remarkably, Summers et al. suggested chronic psychological
stress as a risk factor and acute stress as a triggering factor of TTC
(34). Psychoneuroendocrinological seen patients with anxiety
disorders or depression show increased sympathetic responses
to emotional and physical stressors (36). The emotional stress
triggering activation of the autonomic nervous system is
mediated via two neurohumoral axes: the sympathetic-adrenal-
medulla axis with catecholamine release in the adrenal medulla
(immediate activation after stressor) and the HPA axis (activation
via chronic stressors) with consecutive cortisol release from the
adrenal cortex (36). Notably, also low cortisol blood levels have
been reported in patients with chronic stress as compensatory
mechanism to avoid hypercortisolism (36). Thus, the inhibitory
effects of catecholamine release through high cortisol blood levels
disappear and which can result in myocardial stunning (36).
However, in order to further elucidate the neuroendocrinological
mechanisms in TTC, future studies with larger patient cohorts
under controlled study surroundings are necessary.
Further, type-D-personality is a controversial debated risk
factor of TTC (2). Interestingly, one study revealed pre-existing
psychiatric illness is related with an increased risk of TTC, but
not an increased 30 day or long-term mortality (37).
DIAGNOSTIC OF TAKOTSUBO
CARDIOMYOPATHY
The most important clinical tool in diagnosing TTC appears to
be an accurate anamnesis of emotional and physical events prior
to the onset of the patient’s symptoms, if possible. Additionally,
assessment of the patient’s medical history, particularly of
preexisting psychiatric and neurological diseases, is fundamental
in the diagnostical workflow of TTC. As clinical presentation
of ACS and TTC patients is similar, firstly blood levels of
cardiac enzymes are obtained. Commonly, troponin as marker
of cardiomyocytes necrosis is elevated, whereas the creatine
kinase is usually only slightly elevated in TTC patients (8).
High troponin values were shown to be a predictor of a worse
in-hospital outcome, because of e.g., the occurrence of malign
arrhythmias (8). However, there are patients where troponin
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is either slightly or not elevated, which led to the term of
disproportionately troponin elevation if compared to the seen
wall motion abnormalities in TTC patients (6). In general, peak
values of troponin blood levels are lower than in patients with
ACS (8). An important clinical marker of TTC is elevation
of N-terminal prohormone of brain natriuretic peptide (NT-
proBNP), which has been shown to be associated directly with
the degree of increased blood concentration of catecholamines
as a marker of sympathetic overreaction and the severity of left
ventricular dysfunction with associated systemic complications,
such as pulmonary edema (38). ECG is routinely performed
mainly to rule out acute coronary syndrome and myocarditis as
differential diagnosis of TTC. Moreover, >95% of TTC patients
show ECG abnormalities during the acute phase (3).
ELECTROCARDIOGRAM
The electrocardiogram (ECG) can be either completely
unremarkable or shows ST-segment elevations or ST-segment
depression in leads II, III, aVF, aVR, and V5 to V6 (2).
Further, T wave inversions suggestive for cardiac repolarization
abnormalities can occur in ECGs of TTC patients (39).
Prolongation of QT-Intervals (>500ms) indicate a higher risk
for the occurrence of malign and potential life-threatening
arrhythmias, such as torsades de pointes and ventricular
fibrillation (3, 40). Consequently, close monitoring of ECG
and haemodynamic parameters is recommended in TTC
patients. Interestingly, recent clinical studies focused on QT
prolongation and inflammatory processes in TTC patients.
Song et al. have found significant higher levels of c-reactive
protein in TTC patients presenting with QT prolongation
in a retrospective analysis (40). Perazzolo et al. correlated
the pathophysiological ECG changes in TTC patients with
myocardial changes in T2-weighted signal cardiac MRI (41).
In this study a correlation of apicobasal gradient of myocardial
edema and dynamic T wave inversions and QT prolongation,
indicating a dispersion of repolarization between apical and
basal myocardial regions have been described (41). Elevated
catecholamine blood concentrations are postulated as mutual
pathophysiological element in TTC and SAH patients. Over the
last decades various studies revealed a possible link between local
cardiac sympathetic disruptions and reversible T-wave changes
in ECG and is together seen with QTc-prolongation (42).
To differentiate TTC patients with ST-Elevations in ECG
from ACS patients and also patients with non ST-Elevations,
which are hemodynamically unstable and suspected TTC (typical
wall motion abnormalities in TTE) patients need to undergo
urgent coronary angiography to exclude relevant stenosis of
the coronary arteries (8). In 2018 the InterTAK Diagnostic
Score as part of the International expert consensus document
on Takotsubo syndrome was published and suggested to be
utilized in patients with no ST-elevations in ECG, but high
probability of TTC (2). By use of the InterTAK Diagnostic
Score patients with symptoms suggestive for an ACS and TTC
patients with no ST-elevations in the ECG are distinguished
(Table 2) (8). The InterTAK Diagnostic Score is positive,
if ≥70 points are achieved. In these patients TTE is the
recommended as next diagnostical step. Patients achieving ≤70
points are recommended to undergo coronary angiography
with left ventriculography. Hemodynamically stable patients,
with visualized TTC typical wall motion abnormalities and
positive InterTAK Diagnostic Score are recommended to receive
a coronary computed tomography angiography to visualize
coronary status (8).
Prior the publication of the InterTAK Diagnostic Score of
TTC the modified Mayo Clinic Criteria of TTC were commonly
used to diagnose TTC in clinical routine (Table 3) (43). Another
diagnostical definition was released by the European Society
of Cardiology extending the modified Mayo Clinic Criteria of
TTC (Table 4) (3).
THERAPEUTIC STRATEGIES OF
TAKOTSUBO CARDIOMYOPATHY
The International expert consensus document on Takotsubo
syndrome provides the most important strategies in treatment
of TTC. Hence the clinical presentation of TTC patients is
similar to ACS patients, prehospital treatment of TTC is
identical to patients with ACS. It is recommended in TTC
patients presenting in cardiogenic shock to avoid catecholamine
treatment, as their use have shown higher mortality rates in
TTC patients, which seems to be consistent with the assumed
underlying pathophysiological mechanisms of TTC (8, 44). In
the presence of left ventricular outflow tract obstruction after-
load reducing medication is contraindicated. TTC Patients with
TABLE 2 | International Takotsubo diagnostic criteria score (InterTAK
diagnostic score).
25 points Female sex
24 points Emotional stress
13 points Physical stress
12 points No ST-segment depression
11 points Psychiatric disorders
9 points Neurological disorders
6 points QTc-Interval prolongation
TTC, Takotsubo cardiomyopathy.
Modified from Ghandri et al. (8).
TABLE 3 | Modified Mayo Clinic diagnostical criteria of
Takotsubo cardiomyopathy.
1. Transient hypokinesis, akinesis, or dyskinesis in the left ventricular mid
segments with or without apical involvement; regional wall motion
abnormalities that extend beyond a single epicardial vascular distribution; and
frequently, but not always, a stressful trigger.
2. Absence of obstructive coronary disease or angiographic evidence of acute
plaque rupture.
3. New ECG abnormalities (ST-segment elevation and/or T-wave inversion) or
modest elevation in cardiac troponin.
4. Absence of pheochromocytoma and myocarditis.
ECG, Electrocardiogram.
Modified from Akashi et al. (43).
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TABLE 4 | Diagnostic criteria for Takotsubo cardiomyopathy of the European
Society of Cardiology.
1. Transient regional wall motion abnormalities of LV or RV myocardium which
are frequently, but not always, preceded by a stressful trigger (emotional
or physical).
2. The regional wall motion abnormalities usually extend beyond a single
epicardial vascular distribution, and often result in circumferential dysfunction
of the ventricular segments involved.
3. The absence of culprit atherosclerotic coronary artery disease including acute
plaque rupture, thrombus formation, and coronary dissection or other
pathological conditions to explain the pattern of temporary LV dysfunction
observed (e.g., hypertrophic cardiomyopathy, viral myocarditis).
4. New and reversible ECG abnormalities (ST-segment elevation, ST depression,
LBBB, T-wave inversion, and/or QTc prolongation) during the acute phase
(3 months).
5. Significantly elevated serum natriuretic peptide (BNP or NT-proBNP) during
the acute phase.
6. Positive but relatively small elevation in cardiac troponin measured with a
conventional assay (i.e., disparity between the troponin level and the amount
of dysfunctional myocardium present).
7. Recovery of ventricular systolic function on cardiac imaging at follow-up
(3–6 months).
BNP, B-type natriuretic peptide; ECG, Electrocardiogram; LBBB, Left Bundle
Branch Block; LV, left ventricular; NT-proBNP, NT-proB-type Natriuretic Peptide; RV,
right ventricular.
Modified from Lyon et al. (3).
primary pump failure may need mechanical left ventricular
assist devices or an establishment of venoarterial-extracorporeal
membrane oxygenation. Also, in cases of mild TTC close
monitoring of patients in an intensive care unit setting is
necessary to detect and treat possible arrhythmias adequately.
Long term medication with beta-blockers after discharge from
hospital, if not contraindicated, should be evaluated. However,
randomized studies with large patients cohorts focusing on long-
term treatment of TTC are needed.
CONCLUSION
In conclusion, TTC is an acute and reversible cardiac disease,
which is associated with acute dysfunction of the central
and autonomic nervous system. However, detailed molecular
mechanisms need to be further elucidated, as the role of
circulating and synaptic catecholamines as part of the autonomic
nervous system are in their precise pathophysiological role
unclear. Beside psychiatric disorders neurological disorders,
especially acute neurological disorders have been shown to
be associated with the occurrence of TTC. Cardiac enzymes
are elevated in most TTC cases. Ultimately, every patient
with suspected TTC needs visualization of myocardial wall
motion in either TTE and/or coronary catheterization with
left ventriculography depending on patient’s hemodynamic
stability. Non-specific ECG changes in TTC patients are
reported, however the initial ECG can show either ST-segment
elevations or ST-segment depressions, as well as negative
T-waves and QTc-Interval prolongation in the initial ECG
Acute treatment of TTC depends on patient’s vitals and the
occurrence of possible complications, like left ventricular
outflow tract obstruction or wall ruptures. In most cases
close monitoring for cardiac arrhythmia and symptomatic
therapy is sufficient. In order to understand TTC in more
detail and to develop specific cardiac diagnostical tools and
therapeutic strategies both molecular and clinical research need
to be performed in future. However, the recently published
International expert consensus document on Takotsubo
syndrome allows an extensive clinical characterization of TTC
and should be used in daily clinical routine to provide excellent
patient care.
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